You are here » Home » Companies » Company Overview » Lupin Ltd

Lupin Ltd.

BSE: 500257 Sector: Health care
NSE: LUPIN ISIN Code: INE326A01037
BSE LIVE 14:43 | 23 Oct 1037.25 -15.25
(-1.45%)
OPEN

1052.35

HIGH

1056.00

LOW

1029.45

NSE 14:34 | 23 Oct 1037.00 -14.20
(-1.35%)
OPEN

1058.00

HIGH

1058.30

LOW

1028.00

OPEN 1052.35
PREVIOUS CLOSE 1052.50
VOLUME 30608
52-Week high 1572.25
52-Week low 920.00
P/E 19.40
Mkt Cap.(Rs cr) 46,868
Buy Price 1037.05
Buy Qty 18.00
Sell Price 1037.90
Sell Qty 67.00
OPEN 1052.35
CLOSE 1052.50
VOLUME 30608
52-Week high 1572.25
52-Week low 920.00
P/E 19.40
Mkt Cap.(Rs cr) 46,868
Buy Price 1037.05
Buy Qty 18.00
Sell Price 1037.90
Sell Qty 67.00

Lupin Ltd. (LUPIN) - Company History

Lupin Ltd is an India-based pharmaceutical company. The company produces a range of generic and branded formulations and Active Pharmaceutical Ingredients (APIs). The company's product basket consists of formulations from Cephalosporins CVS CNS Anti-Asthma Anti-TB Diabetology Dermatology GI and other therapy segments. The company's drug delivery platforms include Bioadhesive/Gastroretentive Extended Release Laser-Drilled Extended Release Matrix/Coated Extended Release Taste Masking Technologies and Improved Bioavailability through Solubilizationand Nano-particle technology. Their APIs products include antibiotics Antibiotics ANTI-TB Cardiovasculars Central Nervous System Analegesics and ANTI-GOUT. Lupin Ltd was incorporated in the year 1983 with the name Lupin Chemicals Ltd. In the year 1987 the company commenced operations in Cephalexin Plant at Mandideep and 7 ADCA plant at Ankleshwar. In the year 1989 the company established a joint venture in Thailand namely Lupin Chemicals (Thailand) Ltd. In the year 1991 they initiated production of Injectable cephalosporin (bulk and dosages) at Mandideep. In the year 1992 the company set up Fermentation Plant at Tarapur Maharashtra. Also Sterile Plant for injectable Cephalosporins (bulk) was commissioned at Mandideep.In the year 2001 Lupin Laboratories Ltd was amalgamated with the company and the name was changed to Lupin Ltd. They commenced supply of Cephalosporin bulk actives to their alliance partners in the US. Also they commissioned a state of the art US FDA approvable oral cephalosporin bulk active plant. In the year 2002 the company commissioned the new Anti-TB facility at Aurangabad. In the year 2003 they formed Lupin Pharmaceuticals Inc. USA for trading marketing and developmental activities in the US. In the year 2006 the company set up a new facility at Jammu.In the year 2007 the company acquired Vadodara based Rubamin Laboratories Ltd (rechristened to Novodigm Ltd). Also they acquired Kyowa Pharmaceutical Industry Company Limited a leading Generic Company in Japan. They started commercial production at their newly finished dosage facility at Jammu. Also they set a new finished dosage facility at Indore.During the year 2008-09 the company expanded their product basket in Japan-Kyowa and received ten products approval from Ministry of Health & Labour Welfare Japan. They acquired 100% stake in Hormosan Pharma GmbH a generic company in Germany. Also they acquired 36.65% stake in Generic Health Pty Ltd. in Australia 60% stake in Pharma Dynamics in South Africa and 51% stake in Multicare Pharmaceuticals Philippines Inc in Philippines.During the year 2009-10 Lupin (Europe) Ltd UK and Lupin Pharma Canada Ltd Canada were incorporated on June 5 2009 and June 18 2009 respectively. Lupin Holding B V the Netherlands transferred their holdings in Max Pharma Pty Ltd Australia a wholly owned subsidiary of the company to Generic Healthy Pty Ltd Australia an associated of the company upon which Max Pharma Pty Ltd ceased to be a subsidiary of the company with effect from May 31 2009. In January 2010 as per the scheme of amalgamation Novodigm Ltd Lupin Pharmacare Ltd and Lupin Herbal Ltd wholly owned subsidiaries of the company were amalgamated with the company with effect from April 1 2009.In August 23 2010 the company incorporated Lupin Mexico SA de CV Mexico as a subsidiary company. The company increased their stake in Generic Health Pty Ltd. (Generic) Australia from 49.91% to 76.65% and thus Generic became a subsidiary of the company with effect from September 27 2010. Consequently Bellwether Pharma Pty Ltd. Australia Generic Health Inc. U.S.A. and Max Pharma Pty Ltd. Australia which were subsidiaries of Generic became subsidiaries of the company with effect from September 27 2010. The company incorporated Lupin Philippines Inc. Philippines and Lupin Healthcare Ltd. India as subsidiaries on December 20 2010 and March 17 2011 respectively.In June 2011 the company's Generic Healthy Pty Ltd acquired worldwide rights for the Goanna Brand and the complete range of premium therapeutic oils rubs and ointments marketed under the brand. In July 2011 the company entered into a research and development agreement with Medicis Pharmaceutical Corporation (Medicis) to apply Lupin technologies to multiple therapeutic compounds. In November 2011 the company acquired I'rom Pharmaceuticals through their Japanese subsidiary.In 2012 the company receives Tentative Approval for Generic Glumetza Extended-Release Tablets. The company announces settlement with SANTARUS and DEPOMED for GLUMETZA Patent Litigation. The company also launches Generic Geodon Capsules and Generic SEROQUEL Tablets during the year under review.In 2013 the company inaugurated new Plant at Nagpur. The company got Mahindra Samridhhi India Agri National Award for Bee keeping and Honey Production. In 2014 the company acquires Laboratorios Grin S.A. De C.V. Mexico; a Specialty Ophthalmic Company. The company enters the Latin American Market. The company also acquires Nanomi B.V. and enters Complex Injectables Space. The company receives FDA Approval for Generic Actos Tablets and Generic Celebrex Capsules.In 2015 the company launches Generic DIOVANr Tablets. The company receives FDA Approval for Generic Vancocin Capsules. During the year under review the company and Celon announce Strategic Development and Licensing Agreement for Generic Advair Diskus. The company and Rotary Join Hands to Combat Tuberculosis in Mumbai. The company introduces generic hypertension drug in US. The company receives various awards like UBM India Pharma Awards 2015 CNBC India Risk Management Awards etc. The company also acquires Biocom in Russia during the year under review.